



Corporate Presentation

Nasdaq: PRTG April 2022



Legal Disclaimer

This presentation is for information purposes only. This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction. Such an offer can only be made by prospectus or other authorized offering document. This presentation and materials or fact of their distribution or communication shall not form the basis of, or be relied on in connection with any contract, commitment or investment decision whatsoever in relation thereto. No securities commission or similar authority in Canada, the United States or any other jurisdiction has in any way passed upon the adequacy or accuracy of the information contained in this presentation.

Forward-Looking Information

This presentation contains "forward-looking statements" that involve risks and uncertainties. Our actual results could differ materially from those discussed in the forward-looking statements. The statements contained in this presentation that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the "Securities Act," and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "strategy," "target," "will," "would" and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in our reports filed with the Securities and Exchange Commission from time to time. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

A shelf registration statement on Form F-3 relating to the public offering of the Company's common stock was declared effective by the Securities and Exchange Commission on March 8, 2021. Before you invest, you should read the prospectus in the registration statement and related preliminary prospectus supplement that the Company will file with the Securities and Exchange Commission for more complete information about the Company and the offering. An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering will be available on the website of the Securities and Exchange Commission at www.sec.gov. Copies of the preliminary prospectus supplement, when available, and the accompanying prospectus relating to the offering may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.



Driving the development of first-in-class immunooncology therapies to help more patients achieve durable treatment responses and a better quality of life



Who We Are





A Proven Team With Oncology & Financing Expertise



Founding management team with unique insights in immuno-oncology (helped BMS develop Yervoy & Opdivo)

Gregory Bailey, MD

Founded and financed companies that have exceeded \$20 billion in market cap including Medivation (NASDAQ: MDVN), Ascent Health Care and Biohaven (NYSE: BHVN)

Linda M. Kozick

Former commercial strategy leader at BMS. 25 years experience in oncology, 15 years experience in immuno-oncology space.

Jim Mellon

Author, Entrepreneur & Investor. Co-author of 5 books. Founder and Chairman of Juvanescence.

Steven Mintz

Entrepreneurial financial consultant. President of St. Germain Capital Corp, CFO of Minkids Group.


Mark Simon

Former investment banker and research analyst. Co-founder and advisor of Torreya Capital, LLC. 30 year veteran in life sciences, including investment banking and research analyst.

5 Blockbuster Oncology Approvals, Several Billion \$ Exits



Success Is More Than Good Science





iNKT agonists PORT-2, PORT-3

Activate the innate and adaptive immune system to recognize & attack tumors







Our iNKT Agonists: Addressing Checkpoint Resistance

Platform	Technology	Asset	Preclinical	Phase 1	Phase 2	Data Timing	Strategy
PORT-2	iNKT agonists - Liposomal Formulations	IMM60	Melanoma			Phase 1/2 Initial	Monotherapy in immunogenic tumors
		IMM60 + KEYTRUDA	Melar	noma		Efficacy Data Expected End 2022	Convert PDL1 negative to positive
		IMM60 + KEYTRUDA	NSC				Reverse PD1 resistance
		IMM60 + cell therapy	Solid Tumors				Improve manufacturing + boost activity
PORT-3	iNKT agonists - Nanoparticle Co-Formulations	(IMM60/ + KE¥TRUDA *	NY-ESO Pos	ive Tumors		Phase 1/2 Preliminary Efficacy Data	Enhance I/O in low
			NY-ESO Blade	der & Ovarian		expected Early 2023	mutational burden tumors



Relevance to cancer: iNKT levels in cancer patients are prognostic

Disease-Specific Survival

Head & Neck Squamous Cell Carcinoma

Overall Survival


(n = 12) (n = 23)(n = 23) (n = 12)(n = 12)P = .0140P = .0027 Months From Start of Radiotherapy Months From Start of Radiotherapy **Locoregional Control Incidence of Distant Metastases** P = .0102(n = 11)(n = 22)(n = 12)_____ __ (n = 12) _____ (n =12) P = .0050(n = 23) Months From Start of Radiotherapy Months From Start of Radiotherapy < 48 iNKT/10⁶ T cells 48-242 iNKT/10⁶ T cells >242 iNKT/10⁶ T cells ____

(n = 12) (n = 23) • More iNK1


- More iNKTs associated with better prognosis in patients
- Deficiency of iNKT in animals leads to cancer formation



iNKT agonist (IMM60) stimulates both the adaptive and innate immune system and corrects the TME for an anti-cancer response/



Multiple cell types involved with anti-cancer response




Portage's small molecule drug can impact all these pathways, including changing the tumor directly




Effect of IMM60 on the number of B16 melanoma lung metastases, superior to a PD1 antibody






PORT-2 shows **better** response rates vs anti-PD-1 in melanoma animals






Subsidized by the University of Oxford

Subsidized Trial with Best-in-Class Design in NSCLC and Melanoma (slide 2 of 3)



Subsidized by the University of Oxford

Subsidized Trial with Best-in-Class Design in NSCLC and Melanoma (slide 3 of 3)



Phase 1/2 trial is subsidized by the University of Oxford



PORT-2


Injection of IMM60 with Soluble Ovalbumin Results in Rejection of Ovalbumin Expressing Tumors



B16-OVA model Injection of IMM60 with soluble ovalbumin results in rejection of ovalbumin expressing tumours 140 120 100 Mean Tumor Size (mm²) 80 Treat 60 40 20 10 5 15 0 **Days After Tumor Challenge** ThrCer 7 + Ova ——ThrCer + Ova ThrCer 6 + Ova -Ova α -GalCer + Ova Naive PORT 3

PORT-2 (ThrCer6) superior to α -Galcer, tumor immunity

PLGA co-formulation with vaccine enhances killing and Antigen specific CD8's






PORT-3


Platform has monotherapy activity and strong synergy with checkpoints







Platform For Creating Immune Priming Agent Co Formulated With Antigens






19 Source: https://clinicaltrials.gov/ct2/show/NCT04751786

Cell Therapy: iNKT agonists can be used as a universal agent to boost responses with and without other therapies

Cell therapy with T, NK and NKT cells is showing promise in many areas of oncology, mainly in hematology

NKT cells can be exploited¹ and used off-the-shelf, potentially in combination with our iNKT agonists



Promising early data in solid tumors:

- alpha GC pulsed APCs + iNKT cells in head & neck resulted in 5/10 patients achieving a PR²
- Jan. 21, 2021 Kuur Therapeutics, announces 1PR+1CR out of 10 evaluable neuroblastoma pts after receiving allogeneic CAR-NKT therapy


Our next area of research: PORT-2 augmenting cell therapy



Platform Expands Size and Addressable PD1 Population

Potential Revenue Impact of iNKT Pipeline





Revenue

Our Pipeline: Diverse, First In Class I/O Agents

Platform	Technology	ŀ	Asset	Preclinical	Phase 1	Phase 2	Phase 3	Data Timing	
PORT-2	iNKT agonists - Liposomal Formulations	IMM60		Melanoma					
		IMM60 +	KEYTRUDA	Melanoma				Initial Efficacy Data End 2022	
		IMM60 +	KEYTRUDA	NSCLC					
		IMM60 + cell therapy		Solid Tumors					
PORT-3	iNKT agonists - Nanopartical Co-Formulations	(IMM60/ NY-ESO-1) +	KEYTRUDA	NY-ESO Po	sitive Tumors			Preliminary Efficacy Data	
				NY-ESO Blac	lder & Ovarian			Early 2023	
PORT-1	Intratumoral Amphiphilic drugs	INT230-6		Ne	eoadjuvant Breast				
		INT230-6 + K	KEYTRUDA		Pancreatic				
					Non MSI CRC				
				Ch	olangiocarcinoma				
					Squamous Cell			Multiple Data Readouts Expected 2H 2022	
		INT230-6 +	YERVOY.		Breast				
					HCC				
					Sarcoma				
		INT230-6			Solid Tumor				
PORT-4	Nanolipogel Co-Formulations	SAUG1 (PD1+VEGF TKI)		Solid Tumor					
		SAUG2 (PD1 + CTLA4)		Solid Tumor				IND in 2023	
PORT-5	VLP-STING	STIM1 + appr	oved agent	Solid Tumor				IND in 2023	

Many Clinical Readouts in 2022-2023



11

Strong U.S. and Global IP Positions on Platforms and Products

Broad and Deep Intellectual Property Covering:

Intratumoral Delivery

- Anti-cancer agent plus penetration enhancer given intratumorally
- Non-covalent binding, non liposome

iNKT Agonists

- Formulations with antigens, other I/O agents
- Liposomes/particles

NANOLIPOGEL & DNA Aptamers

- Optimized co-delivery platforms
- New IP for aptamers
- Composition patents for products

VLP Delivery Platform

 First-in-class systemic STING agonist

Many Applications Pending Worldwide

Issued Patents

>60

2032-2036

Patent Exclusivity



Financial Overview



Summary Financial Data

Cash balance (12/31/2021)	~\$25.6 million	
Debt	\$-	
Shares Outstanding (12/31/2021)	13,343,620	
Insider Ownership	65.83%	
Public Float	34.17%	
Options & RSUs Outstanding (12/31/2021)	1,111,000	
Warrants Outstanding (12/31/21)	33,888	
Net loss (Quarter Ended 12/31/2021)	\$(4.2 million)	
Expected Quarterly Burn	~\$3 million	

Use of Proceeds



Accelerate iNKT clinical trials

Increase countries and sites Additional operational support



New Opportunities

Continue to be opportunistic

Fund IND enabling work

Get 2 additional products ready for clinic



Explore strategic deals Partnerships, collaborations





Why Portage?

We're an engine for accelerated development in untapped, high-growth opportunity areas of the complex I/O market



Portage has screened 100's of opportunities

Hand-picked 10+ first-in-class/best-in-class assets

Diverse portfolio and types of business deals that can be conducted with partners (M&A, build-to-by, license, etc.) >10 clinical data reads in next 1-2 years

Experienced & proven team

Leverage former BMS I/O experienced team


Proven success accelerating the growth of Biohaven to > \$8B MC and commercial product

Capital efficient

Modest initial capital outlay & 2-year cash runway Leverage shared services Invest more heavily behind promising assets

Become a preferred partner for pharma in I/O

Frequent engagement with big pharma and biotech



PD1 Combination Study Landscape







Corporate Presentation

Nasdaq: PRTG April 2022

